NAS:REPH (USA) Also trade in: Germany

Recro Pharma Inc

$ 9.39 0.1 (1.08%)
Volume: 159,005 Avg Vol (1m): 490,781
Market Cap $: 208.28 Mil Enterprise Value $: 256.21 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -10.87
Net Current Asset Value -4.8
Tangible Book -2.6
Projected FCF -8.53
Median P/S Value 6.26
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.55
Cash-To-Debt ranked lower than
81.73% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
REPH: 0.55
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 0.82, Max: 10000
Current: 0.55
0
10000
Equity-to-Asset -0.11
Equity-to-Asset ranked lower than
89.65% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
REPH: -0.11
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.13, Med: 0.22, Max: 0.39
Current: -0.11
-0.13
0.39
Debt-to-Equity -5.57
Debt-to-Equity ranked lower than
94.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
REPH: -5.57
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -5.57, Med: 0.5, Max: 4.04
Current: -5.57
-5.57
4.04
Debt-to-EBITDA -3.42
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
REPH: -3.42
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -31.2, Med: -3.53, Max: -1.34
Current: -3.42
-31.2
-1.34
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.68
DISTRESS
GREY
SAFE
Beneish M-Score -2.91
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -218.57%
WACC 9.64%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -48.15
Operating Margin ranked higher than
57.83% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
REPH: -48.15
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -69.5, Med: -46.91, Max: -6.32
Current: -48.15
-69.5
-6.32
Net Margin % -83.56
Net Margin ranked higher than
54.55% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
REPH: -83.56
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -103.07, Med: -56.64, Max: 5.84
Current: -83.56
-103.07
5.84
ROE % -1437.75
ROE ranked lower than
84.73% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
REPH: -1437.75
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -3595.87, Med: -99.7, Max: 10.23
Current: -1437.75
-3595.87
10.23
ROA % -39.75
ROA ranked higher than
51.20% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
REPH: -39.75
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -11042.31, Med: -99.35, Max: 3.81
Current: -39.75
-11042.31
3.81
ROC (Joel Greenblatt) % -90.37
ROC (Joel Greenblatt) ranked higher than
65.15% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
REPH: -90.37
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -218000, Med: -126.38, Max: -26.84
Current: -90.37
-218000
-26.84
3-Year Total Revenue Growth Rate 14.20
3-Year Revenue Growth Rate ranked lower than
100.00% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
REPH: -14
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -14
Current: -14
0
-14
3-Year Total EBITDA Growth Rate -263.10
3-Year EBITDA Growth Rate ranked lower than
51.12% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
REPH: -173.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -173.6, Med: -36.8, Max: 24.7
Current: -173.6
-173.6
24.7

» REPH's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:REPH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XKRX:220250 TPE:1720 ROCO:4152 AMEX:BTX NAS:JNCE OSTO:ATORX NAS:SNDX NAS:VBIV AMEX:CRMD XKRX:049960 NAS:CHMA NAS:SYBX NAS:PTE ROCO:4128 NAS:CUE NAS:NBRV XPAR:COX TSX:IMV AMEX:PFNX XKRX:067370
Traded in other countries RAH.Germany
Address 490 Lapp Road, Malvern, PA, USA, 19355
Recro Pharma Inc is a specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that develops non-opioid products for the treatment of acute pain. The company operates two divisions Acute Care division and a contract development and manufacturing or CDMO division. The Acute Care division is engaged in developing products for hospital and related settings. Its lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. The CDMO division develops and manufactures pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. The majority of the company's revenue is generated from its CDMO segment.

Ratios

Current vs industry vs history
PS Ratio 2.37
PS Ratio ranked higher than
91.87% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
REPH: 2.37
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.76, Med: 1.6, Max: 6.96
Current: 2.37
0.76
6.96
EV-to-EBIT -6.60
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
REPH: -6.6
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -22.4, Med: -4.4, Max: -1.9
Current: -6.6
-22.4
-1.9
EV-to-EBITDA -8.34
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
REPH: -8.34
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -62.6, Med: -5.8, Max: -2.6
Current: -8.34
-62.6
-2.6
EV-to-Revenue 3.04
EV-to-Revenue ranked higher than
91.70% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
REPH: 3.04
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.7, Med: 1.9, Max: 8.6
Current: 3.04
0.7
8.6
Current Ratio 3.56
Current Ratio ranked lower than
81.84% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
REPH: 3.56
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 2.85, Max: 36.64
Current: 3.56
0.01
36.64
Quick Ratio 3.18
Quick Ratio ranked lower than
78.96% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
REPH: 3.18
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 2.29, Max: 36.64
Current: 3.18
0.01
36.64
Days Inventory 76.30
Days Inventory ranked higher than
65.90% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
REPH: 76.3
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 58.43, Med: 86.96, Max: 88.81
Current: 76.3
58.43
88.81
Days Sales Outstanding 71.43
Days Sales Outstanding ranked higher than
59.73% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
REPH: 71.43
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 49.22, Med: 57.55, Max: 71.43
Current: 71.43
49.22
71.43
Days Payable 81.75
Days Payable ranked lower than
53.92% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
REPH: 81.75
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 20.21, Med: 39.37, Max: 81.75
Current: 81.75
20.21
81.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -32.60
3-Year Share Buyback Rate ranked lower than
78.18% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
REPH: -32.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -43.6, Med: -35.4, Max: -32.6
Current: -32.6
-43.6
-32.6

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 1.50
Price-to-Median-PS-Value ranked lower than
57.08% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
REPH: 1.5
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.48, Med: 0.96, Max: 3.39
Current: 1.5
0.48
3.39
Earnings Yield (Joel Greenblatt) % -15.23
Earnings Yield (Greenblatt) ranked lower than
81.59% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
REPH: -15.23
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -52.9, Med: -22.7, Max: -4.5
Current: -15.23
-52.9
-4.5

More Statistics

Revenue (TTM) (Mil) $ 82.87
EPS (TTM) $ -3.28
Beta 0.86
Volatility % 91.21
52-Week Range $ 4.78 - 10.32
Shares Outstanding (Mil) 22.18

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y